“Over the past 13 years, I had the greatest opportunity to exploit my passion for science at IPST by contributing to the design, and validation of unique assays which are now routinely run and serve to quantify the efficacy in preclinical drug candidates. My greatest contribution was to see the increase in demand for efficacy services such as the rodent model of pulmonary arterial hypertension (PAH), as well as our intravascular thrombosis and hemostasis models.” Charles completed his doctorate in Pharmacology at the Université de Montreal followed by 4 years of post doctorate studies at the University of Pittsburgh in the Department of Molecular Genetics and Biochemistry. His field of expertise includes cardiovascular pharmacology and molecular biology.
Connect with Charles-E. Laurent
Platelet aggregation test
Purpose
To assess platelet aggregation properties following test article administration. The test can be design to assess efficacy or safety of an administered compound.
Method
Measurement of platelet aggregation in titrated platelet-rich plasma by recording changes in light transmission following addition of platelet-activating factors (PAF) such as thrombin, collagen or adenosine diphosphate (ADP).
Study outcome
To evaluate the aggregatory or anti-aggregatory effect of the test article.
Compliance
Non-GLP
Species
Rats, rabbits, humans
Charles-E. Laurent
Ph.D., Director of In-Vivo Pharmacology
